Literature DB >> 16530512

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality.

Yasuhito Tanaka1, Fuat Kurbanov, Shuhei Mano, Etsuro Orito, Victor Vargas, Juan I Esteban, Man-Fung Yuen, Ching-Lung Lai, Anna Kramvis, Michael C Kew, Heidi E Smuts, Sergey V Netesov, Harvey J Alter, Masashi Mizokami.   

Abstract

BACKGROUND & AIMS: Molecular evolutionary analysis based on coalescent theory can provide important insights into epidemiologic processes worldwide. This approach was combined with analyses of the hepatitis C virus (HCV) epidemiologic-historical background and HCV-related hepatocellular carcinoma (HCC) in different countries.
METHODS: The HCV gene sequences of 131 genotype 1b (HCV-1b) strains from Japan, 38 HCV-1a strains from the United States, 33 HCV-1b strains from Spain, 27 HCV-3a strains from the former Soviet Union (FSU), 47 HCV-4a strains from Egypt, 25 HCV-5a strains from South Africa, and 24 HCV-6a strains from Hong Kong isolated in this study and previous studies were analyzed.
RESULTS: The coalescent analysis indicated that a transition from constant size to rapid exponential growth (spread time) occurred in Japan in the 1920s (HCV-1b), but not until the 1940s for the same genotype in Spain and other European countries. The spread time of HCV-1a in the United States was estimated to be in the 1960s; HCV-3a in the FSU, HCV-5a in South Africa, and HCV-6a in Hong Kong in the 1960s, mid-1950s, and late 1970s, respectively. Three different linear progression curves were determined by analysis of the relationship between HCV seroprevalence and HCC mortality in different geographic regions; a steep ascent indicated the greatest progression to HCC in Japan, a near horizontal line indicated the least progression in the United States and the FSU, and an intermediate slope was observed in Europe.
CONCLUSIONS: These findings strongly suggest that the initial spread time of HCV is associated with the progression dynamics of HCC in each area, irrespective of genotype.

Entities:  

Mesh:

Year:  2006        PMID: 16530512     DOI: 10.1053/j.gastro.2006.01.032

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

1.  Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink.

Authors:  Katherine A McGlynn; Katrina Hagberg; Jie Chen; Barry I Graubard; W Thomas London; Susan Jick; Vikrant V Sahasrabuddhe
Journal:  J Natl Cancer Inst       Date:  2015-02-26       Impact factor: 13.506

Review 2.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.

Authors:  Mei-Hsuan Lee; Tiffany I Hsiao; Shreenidhi R Subramaniam; An K Le; Vinh D Vu; Huy N Trinh; Jian Zhang; Mingjuan Jin; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Mindie H Nguyen
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

Review 4.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

5.  Accuracy of physician reporting in routine public health surveillance for hepatitis C virus infection.

Authors:  Klaus Jochem; Pascale Leclerc; Emilie Maurais; Claude Tremblay; Joseph Cox
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

Review 6.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 7.  Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review.

Authors:  Georgios Tsoulfas; Polyxeni Agorastou; Andreas Tooulias; Georgios N Marakis
Journal:  Int Surg       Date:  2014 Nov-Dec

8.  A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review.

Authors:  Sonia Roman; Arturo Panduro; Yadira Aguilar-Gutierrez; Montserrat Maldonado; Maclovia Vazquez-Vandyck; Erika Martinez-Lopez; Bertha Ruiz-Madrigal; Zamira Hernandez-Nazara
Journal:  Hepatol Int       Date:  2008-12-19       Impact factor: 6.047

9.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

Review 10.  Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.

Authors:  Douglas C MacDonald; Mark Nelson; Mark Bower; Thomas Powles
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.